Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604509 · ClinicalTrials.gov registry record · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
A Phase 4 study of Cigarette Smoking-Related Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 2,010
- Enrollment target
- 1
- Study location
NCT04604509 is a Phase 4 study of Cigarette Smoking-Related Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 2,010 participants, above the 372-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (440% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04604509, a Phase 4 study of Cigarette Smoking-Related Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,010 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase IV trial investigates how to personalize treatments (such as medications and/or counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and/or drugs such as varenicline and bupropion may help participants quit smoking or change smoking behavior. This trial may also help doctors individualize smoking cessation treatment for participants who do not quit smoking after the first course of treatment.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Varenicline
- DRUG Bupropion Hydrochloride Controlled-release
- DRUG Nicotine Replacement
- OTHER Tobacco Cessation Counseling
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,010 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04604509
The ClinicalTrials.gov registry entry for NCT04604509 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 2,010 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 372-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (440% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cigarette Smoking-Related Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Questionnaire Administration is the first listed.
NCT04604509 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04604509 about?
NCT04604509 is a clinical study titled "Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial". This phase IV trial investigates how to personalize treatments (such as medications and/or counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and/or drugs such as varenicline and bupropion may help participants quit smokin...
What is the current status of trial NCT04604509?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 2,010 participants. The study started on 2020-08-04. Estimated completion is 2028-12-31.
What conditions does trial NCT04604509 study?
This clinical trial studies the following conditions: Cigarette Smoking-Related Carcinoma.
What interventions are being tested in trial NCT04604509?
The interventions under investigation include: Questionnaire Administration (OTHER), Varenicline (DRUG), Bupropion Hydrochloride Controlled-release (DRUG), Nicotine Replacement (DRUG), Tobacco Cessation Counseling (OTHER).
Who is sponsoring clinical trial NCT04604509?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04604509 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoking-Related Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
RECRUITING · NA
-
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)
RECRUITING
-
Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults
RECRUITING · Early Phase 1
-
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
RECRUITING · Phase 2
-
CONNECTing to LungCare
RECRUITING · NA
-
Understanding Tobacco and Cannabis Co-Use Practices: Initiation, Escalation, and Maintenance
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.